Clinical Trial: Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07807384) titled 'Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy' on Aug. 25.

Brief Summary: This study aims to evaluate whether, under a treatment strategy primarily guided by left ventricular ejection fraction (LVEF), dose up-titration in adult patients with symptomatic obstructive hypertrophic cardiomyopathy who have received Mavacamten treatment for at least 12 weeks with a stable maintenance dose (as baseline) and with LVEF >=55% can further reduce left ventricular outflow tract (LVOT) gradient after 24 weeks of treatment. It will also asses...